Immune Cell Therapy - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB506240723

Publication Date:

June 10, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

Immune Cell Therapy is a medical treatment approach that involves modifying a patient's own immune cells, typically T cells, to enhance their ability to recognize and attack cancer cells or other diseases.
The global market for Immune Cell Therapy was estimated to be worth US$ 3435 million in 2023 and is forecast to a readjusted size of US$ 15060 million by 2030 with a CAGR of 23.7% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Immune Cell Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Immune Cell Therapy by region & country, by Type, and by Application.
The Immune Cell Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Cell Therapy.
麻豆原创 Segmentation
By Company
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Kite Pharma
Novartis
Takara Bio
Unum Therapeutics
Segment by Type:
T Cell Therapy
Natural Killer (NK) Cell Therapy
Other
Segment by Application
Stomach Cancer
Lung Cancer
Colorectal Cancer
Esophageal Cancer
Pancreatic Cancer
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Immune Cell Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Immune Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Immune Cell Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Immune Cell Therapy Product Introduction
1.2 Global Immune Cell Therapy 麻豆原创 Size Forecast
1.3 Immune Cell Therapy 麻豆原创 Trends & Drivers
1.3.1 Immune Cell Therapy Industry Trends
1.3.2 Immune Cell Therapy 麻豆原创 Drivers & Opportunity
1.3.3 Immune Cell Therapy 麻豆原创 Challenges
1.3.4 Immune Cell Therapy 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Immune Cell Therapy Players Revenue Ranking (2023)
2.2 Global Immune Cell Therapy Revenue by Company (2019-2024)
2.3 Key Companies Immune Cell Therapy Manufacturing Base Distribution and Headquarters
2.4 Key Companies Immune Cell Therapy Product Offered
2.5 Key Companies Time to Begin Mass Production of Immune Cell Therapy
2.6 Immune Cell Therapy 麻豆原创 Competitive Analysis
2.6.1 Immune Cell Therapy 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Immune Cell Therapy Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Cell Therapy as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 T Cell Therapy
3.1.2 Natural Killer (NK) Cell Therapy
3.1.3 Other
3.2 Global Immune Cell Therapy Sales Value by Type
3.2.1 Global Immune Cell Therapy Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Immune Cell Therapy Sales Value, by Type (2019-2030)
3.2.3 Global Immune Cell Therapy Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Stomach Cancer
4.1.2 Lung Cancer
4.1.3 Colorectal Cancer
4.1.4 Esophageal Cancer
4.1.5 Pancreatic Cancer
4.1.6 Other
4.2 Global Immune Cell Therapy Sales Value by Application
4.2.1 Global Immune Cell Therapy Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Immune Cell Therapy Sales Value, by Application (2019-2030)
4.2.3 Global Immune Cell Therapy Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Immune Cell Therapy Sales Value by Region
5.1.1 Global Immune Cell Therapy Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Immune Cell Therapy Sales Value by Region (2019-2024)
5.1.3 Global Immune Cell Therapy Sales Value by Region (2025-2030)
5.1.4 Global Immune Cell Therapy Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Immune Cell Therapy Sales Value, 2019-2030
5.2.2 North America Immune Cell Therapy Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Immune Cell Therapy Sales Value, 2019-2030
5.3.2 Europe Immune Cell Therapy Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Immune Cell Therapy Sales Value, 2019-2030
5.4.2 Asia Pacific Immune Cell Therapy Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Immune Cell Therapy Sales Value, 2019-2030
5.5.2 South America Immune Cell Therapy Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Immune Cell Therapy Sales Value, 2019-2030
5.6.2 Middle East & Africa Immune Cell Therapy Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Immune Cell Therapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Immune Cell Therapy Sales Value
6.3 United States
6.3.1 United States Immune Cell Therapy Sales Value, 2019-2030
6.3.2 United States Immune Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Immune Cell Therapy Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Immune Cell Therapy Sales Value, 2019-2030
6.4.2 Europe Immune Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Immune Cell Therapy Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Immune Cell Therapy Sales Value, 2019-2030
6.5.2 China Immune Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.5.3 China Immune Cell Therapy Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Immune Cell Therapy Sales Value, 2019-2030
6.6.2 Japan Immune Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Immune Cell Therapy Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Immune Cell Therapy Sales Value, 2019-2030
6.7.2 South Korea Immune Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Immune Cell Therapy Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Immune Cell Therapy Sales Value, 2019-2030
6.8.2 Southeast Asia Immune Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Immune Cell Therapy Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Immune Cell Therapy Sales Value, 2019-2030
6.9.2 India Immune Cell Therapy Sales Value by Type (%), 2023 VS 2030
6.9.3 India Immune Cell Therapy Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Adaptimmune
7.1.1 Adaptimmune Profile
7.1.2 Adaptimmune Main Business
7.1.3 Adaptimmune Immune Cell Therapy Products, Services and Solutions
7.1.4 Adaptimmune Immune Cell Therapy Revenue (US$ Million) & (2019-2024)
7.1.5 Adaptimmune Recent Developments
7.2 Altor Bioscience Corporation
7.2.1 Altor Bioscience Corporation Profile
7.2.2 Altor Bioscience Corporation Main Business
7.2.3 Altor Bioscience Corporation Immune Cell Therapy Products, Services and Solutions
7.2.4 Altor Bioscience Corporation Immune Cell Therapy Revenue (US$ Million) & (2019-2024)
7.2.5 Altor Bioscience Corporation Recent Developments
7.3 Cellectis
7.3.1 Cellectis Profile
7.3.2 Cellectis Main Business
7.3.3 Cellectis Immune Cell Therapy Products, Services and Solutions
7.3.4 Cellectis Immune Cell Therapy Revenue (US$ Million) & (2019-2024)
7.3.5 Juno Therapeutics Recent Developments
7.4 Juno Therapeutics
7.4.1 Juno Therapeutics Profile
7.4.2 Juno Therapeutics Main Business
7.4.3 Juno Therapeutics Immune Cell Therapy Products, Services and Solutions
7.4.4 Juno Therapeutics Immune Cell Therapy Revenue (US$ Million) & (2019-2024)
7.4.5 Juno Therapeutics Recent Developments
7.5 Kite Pharma
7.5.1 Kite Pharma Profile
7.5.2 Kite Pharma Main Business
7.5.3 Kite Pharma Immune Cell Therapy Products, Services and Solutions
7.5.4 Kite Pharma Immune Cell Therapy Revenue (US$ Million) & (2019-2024)
7.5.5 Kite Pharma Recent Developments
7.6 Novartis
7.6.1 Novartis Profile
7.6.2 Novartis Main Business
7.6.3 Novartis Immune Cell Therapy Products, Services and Solutions
7.6.4 Novartis Immune Cell Therapy Revenue (US$ Million) & (2019-2024)
7.6.5 Novartis Recent Developments
7.7 Takara Bio
7.7.1 Takara Bio Profile
7.7.2 Takara Bio Main Business
7.7.3 Takara Bio Immune Cell Therapy Products, Services and Solutions
7.7.4 Takara Bio Immune Cell Therapy Revenue (US$ Million) & (2019-2024)
7.7.5 Takara Bio Recent Developments
7.8 Unum Therapeutics
7.8.1 Unum Therapeutics Profile
7.8.2 Unum Therapeutics Main Business
7.8.3 Unum Therapeutics Immune Cell Therapy Products, Services and Solutions
7.8.4 Unum Therapeutics Immune Cell Therapy Revenue (US$ Million) & (2019-2024)
7.8.5 Unum Therapeutics Recent Developments
8 Industry Chain Analysis
8.1 Immune Cell Therapy Industrial Chain
8.2 Immune Cell Therapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Immune Cell Therapy Sales Model
8.5.2 Sales Channel
8.5.3 Immune Cell Therapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Kite Pharma
Novartis
Takara Bio
Unum Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.